SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as traders focus on the anticipated Phase 3 ORIGIN 3 eGFR analysis readout expected in the third quarter. Discussion highlights a divide between investors anticipating a positive catalyst or potential acquisition, and others expressing concern over competition and recent price volatility.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending due to rising oil prices fueled by escalating geopolitical tensions in the Middle East, particularly following recent U.S. military strikes near the Strait of Hormuz. Community discussion is characterized by intense debate between traders banking on further price increases and those speculating that the rally is a manipulation or unsustainable.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf shares are experiencing downward pressure as traders debate the impact of recent insider selling by the CEO and director, while others view the pullback as a buying opportunity given the company's long-term power infrastructure agreements and institutional interest. Community sentiment remains polarized between bearish concerns over executive share sales and recent price weakness versus bullish focus on the firm's data center capacity expansion and sector-wide AI demand.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is currently trending as traders debate the ETF's near-term technical outlook amid a broader discussion on gold's role as a hedge against fiscal instability, high debt, and potential Fed rate policy shifts. Market participants are divided between those anticipating a tactical pullback and others maintaining long-term bullish positions based on the sector's performance relative to physical gold and macroeconomic uncertainty.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is experiencing significant volatility and heavy trading volume as retail traders debate whether the stock is a long-term value opportunity supported by robust share buybacks or a candidate for a major correction following its recent earnings-driven rally. While some traders point to strong fundamentals and potential short squeeze dynamics, skeptics argue that the gains are largely fueled by one-time tariff refunds and caution against overvaluation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are trending lower as escalating military conflict in the Middle East and rising oil prices fuel investor concerns over inflation and potential interest rate hikes. Traders are closely monitoring Treasury yields, which have reached levels not seen since 2007, as the community debates whether the current economic environment points toward a significant market correction.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as traders react to a governance proposal aimed at activating a fee switch and initiating a large-scale token burn, driving optimism about potential deflationary pressure and protocol revenue. Community discussion remains focused on these governance developments alongside the project's strategic role as a core liquidity layer for tokenized assets.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crude oil is receiving attention as traders monitor escalating tensions in the Middle East, specifically involving recent military activity in the Strait of Hormuz, alongside a broader debate regarding whether current oil prices have already priced in the conflict. While some market participants anticipate potential supply disruptions, others point to rising oil production, recovered shipping flows, and increased global renewable capacity as factors supporting a bearish outlook for oil prices.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is experiencing significant volatility as investors debate the impact of high capital expenditures on free cash flow versus the company's strong earnings beats and ongoing demand for AI-related optical connectivity. While some traders view the recent price drop as a buying opportunity, others express concern over institutional selling and weak margins.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as traders analyze the conglomerate's shift back to being a net buyer of equities and the deployment of its massive cash reserves. The community remains divided, with some investors expressing frustration over the stock's long-term performance and the transition to leadership under Greg Abel, while others maintain confidence in the firm's diversified value and long-term capital allocation strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock

Equity

Analysts raised their price targets on RARE stock after the FDA granted accelerated regulatory approval for its rare metabolic disease therapy.


Futures Slide As Treasury Yields Surge, Erasing Bessent Intervention, Driven By Oil Spike

Futures Slide As Treasury Yields Surge, Erasing Bessent Intervention, Driven By Oil Spike

 US futures slide and are trading at session lows,?as bond yields surge after yesterday's Treasury announcement, having now erased the entire post buyback-boost move; yields are 4-5bps higher as...

RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher  

The FDA granted accelerated approval to GENGLYCOS, also called DTX401, for patients aged eight and older with glycogen storage disease type Ia (GSDIa). 


RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy 

The FDA is due to rule by August 23 on Ultragenyx’s application for DTX401, a one-time gene therapy for von Gierke disease. 


Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of +29.13% and +18.23%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Q2 Loss Narrows, Reaffirms 2026 Revenue Outlook

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a narrower net loss for the second quarter, as revenues grew from a year ago. The company reaffirmed its full-year 2026 revenue guidance...

• Reported GAAP EPS of -$0.90 up 23.08% YoY
• Reported revenue of $214M up 28.53% YoY
• Ultragenyx Pharmaceutical Inc. reaffirms its 2026 full-year total revenue guidance of $730 million to $760 million, excluding potential new product launches, while remaining on track toward profitability in 2027.

Ultragenyx Pharmaceutical Inc. continues to report net losses and a declining cash balance, while maintaining significant structural dependency on third-party partners for the commercialization of its primary revenue-generating product.

Ultragenyx Pharmaceutical Inc. achieved record quarterly revenue and remains on a clear path to profitability by 2027, supported by anticipated expense reductions and a robust pipeline of upcoming clinical catalysts.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$25.81
Prev Close	$25.21
Open	$25.22
Dividend Yield	0.00%
50-Day Moving Average	$28.32
Beta	1.13
Avg. Volume	2.13M
PE Ratio	-4.42

52-Week High	$39.89
52-Week Low	$18.29
Market Capitalization	$2.49B
EPS (Annual)	-$5.83
Price to Book	-8.72
Revenue Per Employee	$490,882.57

Feed

News

Sentiment

Earnings

Fundamentals

Info